Eliglustat tartrate (GENZ-112638; Genz-99067; Cerdelga), the tartrate salt of eliglustat, is a specific and orally bioactive glucocerebroside synthase inhibitor (IC50 = 24 nM) that has been approved by the FDA in August 2014 for the treatment for Gaucher’s disease type 1 (GD1).

Eliglustat (GENZ-112638, Genz-99067, GENZ112638, Genz99067, Cerdelga) is a novel, potent, specific and orally bioactive glucocerebroside synthase inhibitor (IC50 = 24 nM) approved by FDA in 2014 for the treatment for Gaucher’s disease.

Miglustat HCl (OGT-918; NB-DNJ; Zavesca) is an FDA approved drug used to treat Type I Gaucher disease (GD1).

Ibiglustat L-Malic acid (Venglustat; GZ402671; Genz-682452; GZ-452; SAR-402671) is a novel and potent inhibitor of glucosylceramide synthase (GCS) and also a ceramide glucosyltransferase inhibitor.

Ibiglustat (formerly Venglustat; SAR-402671; GZ-402671; GZ-452; Genz-682452) is a novel, brain-penetrant, potent and selective allosteric Glucosylceramide synthase (GCS) inhibitor and ceramide glucosyltransferase inhibitor.